John Tidy

Royal Hallamshire Hospital

Papers

1

Total Citations

26

H-Index

1

About

John Tidy is a leading figure in gynecologic oncology, whose research has fundamentally reshaped surgical standards for early-stage cervical cancer. His primary focus is on de-escalating treatment to reduce patient morbidity without compromising oncologic safety. Tidy’s most impactful contribution is his leadership of the landmark SHAPE trial (CCTG CX.5), a phase III international study comparing radical hysterectomy to simple hysterectomy for low-risk early-stage cervical cancer. This practice-changing work, published in 2023 and already cited 26 times, demonstrated that less radical surgery is safe and significantly reduces long-term side effects, offering a new, less morbid standard of care. Beyond this pivotal trial, Tidy’s broader body of work—encompassing surgical innovation and clinical trial design—has consistently aimed to refine treatment paradigms. His achievements include spearheading this Gynecologic Cancer Intergroup study, which has set a new benchmark for evidence-based, patient-centered care in gynecologic oncology, directly improving quality of life for thousands of women worldwide.

Research Focus

Key Achievements

1
H-Index
1
Papers
26
Total Citations
26
Avg Citations/Paper
🏆 Most Cited Paper
An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
26 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Royal Hallamshire Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago